LOCALLY ADVANCED RECTAL CARCINOMA
Clinical trials for LOCALLY ADVANCED RECTAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED RECTAL CARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED RECTAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to save rectums from surgery
Disease control Recruiting nowThis early-phase trial tests whether a short course of radiation followed by chemotherapy can shrink advanced rectal tumors enough to avoid surgery. About 25 people with stage II or III rectal cancer will receive the treatment. The goal is to preserve the rectum and improve quali…
Matched conditions: LOCALLY ADVANCED RECTAL CARCINOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New cocktail aims to shrink rectal tumors before surgery
Disease control Recruiting nowThis study is for people with a certain type of locally advanced rectal cancer (pMMR/MSS) that often doesn't respond well to immunotherapy alone. The trial combines an immunotherapy drug (serplulimab) with chemotherapy (CAPEOX) and an anti-inflammatory drug (celecoxib) to see if …
Matched conditions: LOCALLY ADVANCED RECTAL CARCINOMA
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Heat waves against cancer: new trial tests hyperthermia for rectal tumors
Disease control Recruiting nowThis phase 3 trial tests whether adding modulated electro-hyperthermia (mEHT) to standard treatment helps shrink locally advanced rectal cancer. About 126 adults will receive either standard therapy alone or with mEHT twice a week for six weeks. The goal is to see if the heat-bas…
Matched conditions: LOCALLY ADVANCED RECTAL CARCINOMA
Phase: PHASE3 • Sponsor: Shih-Kai Hung • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Immunotherapy boosts standard treatment for rectal cancer in new trial
Disease control Recruiting nowThis clinical trial is testing whether adding the immunotherapy drug tislelizumab to standard chemoradiation helps people with locally advanced rectal cancer. The study involves 375 participants who will receive either the combination or standard treatment alone. The main goal is…
Matched conditions: LOCALLY ADVANCED RECTAL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC